Switch theme
Sign up to access all valuation multiples
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
1923
10.6K+
LTM Revenue $2.9B
LTM EBITDA $723M
$15.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
West Pharma has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $723M.
In the most recent fiscal year, West Pharma achieved revenue of $2.9B and an EBITDA of $744M.
West Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See West Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| Gross Profit | $998M | XXX | $999M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $723M | XXX | $744M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $563M | XXX | $591M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $473M | XXX | $493M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, West Pharma's stock price is $211.
West Pharma has current market cap of $15.1B, and EV of $15.0B.
See West Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.0B | $15.1B | XXX | XXX | XXX | XXX | $6.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, West Pharma has market cap of $15.1B and EV of $15.0B.
West Pharma's trades at 5.2x EV/Revenue multiple, and 20.2x EV/EBITDA.
Equity research analysts estimate West Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
West Pharma has a P/E ratio of 32.0x.
See valuation multiples for West Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.1B | XXX | $15.1B | XXX | XXX | XXX |
| EV (current) | $15.0B | XXX | $15.0B | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | 20.8x | XXX | 20.2x | XXX | XXX | XXX |
| EV/EBIT | 26.7x | XXX | 25.5x | XXX | XXX | XXX |
| EV/Gross Profit | 15.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.0x | XXX | 30.7x | XXX | XXX | XXX |
| EV/FCF | 50.8x | XXX | 54.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWest Pharma's last 12 month revenue growth is 4%
West Pharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $38K for the same period.
West Pharma's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
West Pharma's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for West Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | -8% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
West Pharma acquired XXX companies to date.
Last acquisition by West Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . West Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was West Pharma founded? | West Pharma was founded in 1923. |
| Where is West Pharma headquartered? | West Pharma is headquartered in United States of America. |
| How many employees does West Pharma have? | As of today, West Pharma has 10.6K+ employees. |
| Who is the CEO of West Pharma? | West Pharma's CEO is Mr. Eric Mark Green. |
| Is West Pharma publicy listed? | Yes, West Pharma is a public company listed on NYS. |
| What is the stock symbol of West Pharma? | West Pharma trades under WST ticker. |
| When did West Pharma go public? | West Pharma went public in 1980. |
| Who are competitors of West Pharma? | Similar companies to West Pharma include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of West Pharma? | West Pharma's current market cap is $15.1B |
| What is the current revenue of West Pharma? | West Pharma's last 12 months revenue is $2.9B. |
| What is the current revenue growth of West Pharma? | West Pharma revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of West Pharma? | Current revenue multiple of West Pharma is 5.2x. |
| Is West Pharma profitable? | Yes, West Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of West Pharma? | West Pharma's last 12 months EBITDA is $723M. |
| What is West Pharma's EBITDA margin? | West Pharma's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of West Pharma? | Current EBITDA multiple of West Pharma is 20.8x. |
| What is the current FCF of West Pharma? | West Pharma's last 12 months FCF is $296M. |
| What is West Pharma's FCF margin? | West Pharma's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of West Pharma? | Current FCF multiple of West Pharma is 50.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
